Nemiralisib HCl (GSK-2269557; GSK2269557) is a novel and potent PI3Kδ inhibitor currently in clinical trials for the treatment of respiratory diseases such as asthma and COPD. GSK-2269557 is highly selective for PI3Kδ over the closely related isoforms. PI3Kδ is overactive in leukocytes, making it an attractive target for the treatment of inflammatory conditions, such as asthma,6 chronic obstructive pulmonary disease (COPD), and autoimmune diseases.

纯度：≥98%

CAS：1254036-77-5